NextPlat Corp’s PharmcoRx subsidiary rolled out an artificial‑intelligence‑powered prescription intake and processing system on April 16, 2026. The new platform automates manual tasks such as data entry, faxing and refill management, creating fully HIPAA‑compliant digital workflows that streamline prescription handling.
The deployment is part of a broader effort to modernize NextPlat’s 340B pharmacy operations and support the expansion of its nationwide fulfillment program. By automating prescription processing, PharmcoRx aims to handle higher prescription volumes while maintaining accuracy and compliance, which could translate into higher margins and stronger client retention in a highly competitive segment.
"At PharmcoRx, we continue to embrace the adoption of modern technology across our pharmacy operations because it can positively impact critical workflows, greatly improve efficiency, accuracy and reduce costs," said Birute Norkute, Vice President of Healthcare Operations. "As we now seek to rapidly expand our services and introduce new, high‑value offerings, we believe the adoption of AI into our prescription processing workflows will enable us to more effectively scale our business while delivering greater value to our customers and patients."
While the press release did not disclose specific financial metrics, the introduction of AI tools aligns with NextPlat’s 2026 breakeven target and reflects the company’s focus on higher‑margin services. The company has been undergoing a turnaround, with significant cost reductions and a shift toward higher‑margin 340B services, and completed a 1‑for‑10 reverse stock split effective April 13, 2026 to meet Nasdaq bid‑price requirements.
PharmcoRx, a subsidiary that focuses on pharmacy and healthcare data management, serves retail pharmacy, 340B program support and long‑term care services. The AI deployment supports the company’s nationwide fulfillment expansion and could improve operational performance by reducing manual effort and enhancing compliance across its pharmacy network.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.